Clearside Biomedical, Inc. (CLSD) — AI Stock Analysis

Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing therapies for the back of the eye through its proprietary suprachoroidal space (SCS) delivery platform. Their lead product, XIPERE, addresses uveitic macular edema, and they are developing additional SCS therapies for other retinal diseases.

Company Overview

TL;DR:

Clearside Biomedical is pioneering targeted ocular therapies with its innovative suprachoroidal space (SCS) delivery platform, offering a novel approach to treating sight-threatening diseases and positioning the company for significant growth in the ophthalmology market with XIPERE and a promising pipeline.

About CLSD

Clearside Biomedical, Inc., founded in 2011 and headquartered in Alpharetta, Georgia, is a biopharmaceutical company dedicated to developing and delivering innovative therapies to restore and preserve vision for people with serious eye diseases. The company's core technology is its proprietary suprachoroidal space (SCS) injection platform, which provides targeted delivery of therapeutic agents to the back of the eye, offering potential advantages over traditional intravitreal injections. Clearside's lead product, XIPERE (triamcinolone acetonide suprachoroidal injectable suspension), is approved for the treatment of uveitic macular edema, a significant cause of vision loss. Beyond XIPERE, Clearside is advancing a pipeline of novel SCS-delivered therapies, including CLS-AX (axitinib injectable suspension) currently in Phase 1/2a clinical trial for retinal diseases and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside has established collaborations with leading pharmaceutical and biotechnology companies, including Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences, to expand the reach and application of its SCS platform. By focusing on unmet needs in retinal disease and leveraging its innovative delivery technology, Clearside aims to become a leader in the ophthalmology market.

Investment Thesis

Clearside Biomedical presents a notable market position based on its innovative SCS delivery platform and its potential to transform the treatment of retinal diseases. XIPERE, the company's first approved product, provides a foundation for revenue growth and validation of the SCS technology. The ongoing clinical development of CLS-AX and CLS-301 offers significant upside potential, addressing large markets with unmet needs. The company's collaborations with established players like Bausch Health and REGENXBIO further de-risk the pipeline and provide access to valuable resources. With a gross margin of 85.6%, Clearside has the potential for strong profitability as its pipeline matures. Key catalysts include the advancement of CLS-AX through clinical trials and potential regulatory approvals for additional indications. Clearside may be worth researching's high beta of 1.79, indicating higher volatility compared to the market.

Industry Context

The ophthalmology market is experiencing significant growth, driven by an aging population and increasing prevalence of diseases such as diabetic macular edema, uveitis, and macular degeneration. Clearside Biomedical is positioned to capitalize on this growth with its innovative SCS delivery platform, which offers a differentiated approach to treating retinal diseases. The competitive landscape includes companies developing intravitreal injections and other drug delivery methods. Clearside's SCS platform offers the potential for improved efficacy and reduced side effects compared to traditional approaches, giving it a competitive advantage. The global ophthalmology market is projected to reach billions of dollars in the coming years, providing a substantial opportunity for Clearside.

Biotechnology

Healthcare

Growth Opportunities

Expansion of XIPERE Label: Clearside has the opportunity to expand the label for XIPERE to include additional indications beyond uveitic macular edema. This could significantly increase the addressable market for the product and drive revenue growth. The market for macular edema related to other conditions is substantial, offering a significant growth avenue for XIPERE. Timeline: Ongoing clinical trials and regulatory submissions.
Development of CLS-AX: CLS-AX, an axitinib injectable suspension for suprachoroidal injection, is currently in Phase 1/2a clinical trial. Successful development and approval of CLS-AX could provide a significant growth driver for Clearside, addressing a large market with unmet needs in retinal diseases. The timeline for this opportunity depends on the clinical trial results and regulatory review process.
Advancement of CLS-301: CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration, represents another significant growth opportunity for Clearside. Successful development and commercialization of CLS-301 could address a large and growing market with significant unmet needs. Timeline: Future clinical trials and regulatory submissions.
Strategic Partnerships: Clearside can pursue additional strategic partnerships with pharmaceutical and biotechnology companies to expand the reach and application of its SCS platform. These partnerships could provide access to valuable resources, accelerate the development of new therapies, and drive revenue growth. Timeline: Ongoing discussions and potential agreements.
Geographic Expansion: Clearside has the opportunity to expand its geographic reach beyond the United States. Entering new markets could significantly increase the addressable market for XIPERE and other products in the pipeline. Timeline: Future regulatory approvals and commercialization efforts in new territories.

XIPERE is the first and only FDA-approved product for suprachoroidal injection for the treatment of uveitic macular edema.
Gross margin of 85.6% demonstrates strong potential for profitability as sales increase.
Collaboration with Bausch Health provides commercialization support for XIPERE.
CLS-AX, an axitinib injectable suspension, is in Phase 1/2a clinical trial, targeting significant unmet needs in retinal diseases.
The company's suprachoroidal space (SCS) injection platform offers targeted drug delivery to the back of the eye.

What They Do

Develops therapies for retinal diseases.
Utilizes suprachoroidal space (SCS) injection platform for targeted drug delivery.
Offers XIPERE for the treatment of uveitic macular edema.
Advances CLS-AX for retinal diseases through clinical trials.
Develops CLS-301 for diabetic macular edema and macular degeneration.
Collaborates with pharmaceutical companies to expand the reach of its technology.

Business Model

Develops and commercializes ophthalmic therapies.
Generates revenue from sales of XIPERE.
Out-licenses its SCS technology to other companies.
Receives milestone payments and royalties from collaborations.

Patients with uveitic macular edema.
Ophthalmologists and retinal specialists.
Pharmaceutical companies through collaborations.
Hospitals and clinics.

Proprietary suprachoroidal space (SCS) injection platform.
FDA approval for XIPERE.
Strong intellectual property portfolio.
Established collaborations with leading pharmaceutical companies.

Catalysts

Upcoming: Clinical trial results for CLS-AX.
Upcoming: Potential regulatory approvals for new indications of XIPERE.
Ongoing: Expansion of commercialization efforts for XIPERE.
Ongoing: New strategic partnerships and collaborations.

Risks

Potential: Clinical trial failures for CLS-AX and CLS-301.
Potential: Regulatory delays or rejections.
Ongoing: Competition from established players in the ophthalmology market.
Ongoing: Reliance on collaborations for revenue.
Potential: Dilution risk through future equity offerings.

Strengths

Innovative suprachoroidal space (SCS) injection platform.
FDA-approved product (XIPERE).
Strategic collaborations with established companies.
Strong gross margin.

Weaknesses

Limited product portfolio.
Reliance on collaborations for revenue.
Negative profit margin.
High beta, indicating higher volatility.

Opportunities

Expansion of XIPERE label.
Successful development of CLS-AX and CLS-301.
Geographic expansion.
New strategic partnerships.

Threats

Competition from existing retinal therapies.
Clinical trial failures.
Regulatory hurdles.
Dilution risk.

Competitors & Peers

Allergan — Offers treatments for retinal diseases. — (ALLR)
CASI Pharmaceuticals, Inc. — Focuses on developing innovative therapeutics. — (CASI)
Cingulate Inc. — Develops therapies for attention deficit hyperactivity disorder (ADHD). — (CING)
Entos Pharmaceuticals Inc. — Develops genetic medicines with Fusogenix delivery platform. — (ENTO)
Kapa Therapeutics, Inc. — Develops RNA therapeutics for cardiovascular diseases. — (KAPA)

Key Metrics

Price: $0.41 (-3.85%)
Market Cap: $3
Volume: NaN
MoonshotScore: 51/100

Analyst Price Target

Analyst Consensus Target: $60.00
Current Price: $0.41
Implied Upside: +14534.1%

常见问题

What does Clearside Biomedical, Inc. (CLSD) do?

Clearside Biomedical, Inc. (CLSD) is a biopharmaceutical company focused on developing and commercializing therapies for sight-threatening diseases. The company's core technology is its proprietary suprachoroidal space (SCS) injection platform, which allows for targeted delivery of therapeutic agents to the back of the eye. Their lead product, XIPERE, is approved for the treatment of uveitic macular edema, and they are developing additional SCS-delivered therapies for other retinal diseases, offering a novel approach to treating these conditions.

Is CLSD stock a good buy?

Evaluating whether CLSD stock is a good buy requires considering several factors. The company has an FDA-approved product, XIPERE, and a promising pipeline of SCS-delivered therapies. However, it also has a negative profit margin of -780.9% and a high beta of 1.79, indicating higher volatility. The success of ongoing clinical trials for CLS-AX and CLS-301 will be critical. Investors should weigh the potential for growth against the inherent risks associated with a small-cap biotechnology company before making a decision.

What are the risks of investing in CLSD?

Investing in CLSD carries several risks typical of small-cap biotechnology companies. These include the risk of clinical trial failures, regulatory hurdles, and competition from established players in the ophthalmology market. Additionally, CLSD has a history of negative profitability and may require additional funding through equity offerings, leading to potential dilution for existing shareholders. The company's reliance on collaborations for revenue also poses a risk if these partnerships are not successful or are terminated.

What catalysts could move CLSD stock?

Several catalysts could potentially move CLSD stock. Positive results from ongoing clinical trials for CLS-AX and CLS-301 would be significant catalysts, as would regulatory approvals for new indications of XIPERE or for the company's pipeline products. New strategic partnerships and collaborations could also drive positive sentiment. Conversely, negative clinical trial results, regulatory setbacks, or the termination of existing partnerships could negatively impact the stock price. Keep an eye on upcoming announcements regarding clinical trial progress and regulatory submissions.

What is CLSD stock price target?

As of March 2, 2026, analyst consensus price targets for CLSD stock are not widely available due to its micro-cap status. Therefore, a definitive price target cannot be stated. Investors should conduct their own due diligence and consider factors such as the company's pipeline progress, regulatory milestones, and financial performance when assessing the potential value of CLSD stock. A fair value estimate would require a detailed financial model incorporating projected revenues, expenses, and discount rates.

Is CLSD a good investment right now?

Use the AI score and analyst targets on this page to evaluate Clearside Biomedical, Inc. (CLSD). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for CLSD?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates Clearside Biomedical, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find CLSD financial statements?

Clearside Biomedical, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.